• Medistim joins GE Vingmed Ultrasound and Sensocure in the development of new production technology.

    Sensocure, GE Vingmed Ultrasound and Medistim have been granted funding of MNOK 14,4 over 3 years from the BIA Health program at the Norwegian Research Council, for the project «Advanced Manufacturing Technologies for High Impact…

    Read more
  • Results for the Third Quarter 2017

    Currency neutral growth of own products is 12.5%. Flow probe sales negatively impacted with MNOK 2.2, however, production of flow probe capacity is improving and backorder is reduced from 500 to 250 probes. Another strong…

    Read more
  • Results for the Second Quarter 2017

    Currency neutral growth of own products was 4.7 % and was negatively impacted by delayed flow probe deliveries amounting to MNOK 5.5. Currency neutral growth of own products was 10.7 % for the 1st half.…

    Read more
  • Preliminary findings from the REQUEST registry study presented at the ICC in New York, USA

    The REQUEST study is a prospective, multicenter registry with leading cardiac surgery centers from Europe, USA and Canada, led by Coordinating Investigator Professor David Taggart from the University of Oxford. The objective is to study…

    Read more
  • Medistim has received clearance for sale of MiraQ™ in China

    MiraQ™ represents Medistim's most advanced system for ultrasonic surgical guidance and quality assessment used intraoperatively during coronary artery bypass grafting (CABG) as well as vascular and transplant surgery. The system combines state-of-the-art transit time blood…

    Read more
  • Results for the First Quarter 2017

    Sales in the first quarter amounted to MNOK 74.4 (MNOK 65.5), a 13.5 % growth. Currency neutral growth of own products was 20.3 %. Sales from the US increases with 9.6 % in USD. In…

    Read more
  • Annual Report 2016

    Sales for the group in 2016 ended at 268.1 MNOK (251.4 MNOK), a 6.6 % growth. Download full report here: Annual Report Medistim 2016

    Read more
  • Results for the Fourth Quarter 2016

    Currency neutral sales of own products decreased with 3 MNOK or 5.7 % due in part to a back order situation on TTFM flow probes. Currency neutral sales of own products increased with 9.5 %…

    Read more
  • Medistim Establishes Own Subsidiary in Spain

    Annually, around 7.000 coronary artery bypass surgery (CABG) procedures and 8.000 vascular procedures are performed throughout the 56 cardiac centers and 75 vascular centers in Spain. Medistim currently has an installed base of 80 systems,…

    Read more
  • Medistim launches the SonoQ™

    (Oslo, November 10th 2016), Medistim ASA (OSE: MEDI), a medtech company that develops and distributes surgical guidance and quality assessment devices, launches the Medistim SonoQ™. In October 2015, Medistim entered into an exclusive License and…

    Read more